Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

"Twenty-five Years of Advanced RadioTherapy (ART), With Intensity Modulation, Image-guidance, and Stereotactic Radiotherapy, With Classic Fractionation, Moderate- or Ultra-hypofractionation at San Raffaele Hospital "

NCT07894900 is registered in ClinicalTrials.gov with IRCCS San Raffaele as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07894900 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
"Twenty-five Years of Advanced RadioTherapy (ART), With Intensity Modulation, Image-guidance, and Stereotactic Radiotherapy, With Classic Fractionation, Moderate- or Ultra-hypofractionation at San Raffaele Hospital "
Lead sponsor
IRCCS San Raffaele
Phase
Observational
Overall status
Not yet recruiting
Start date
November 15, 2026
Completion date
November 15, 2031
Enrollment
10,000 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

Arms

As registered; 20 arms.

  • Lymph nodes Advanced radiotherapy techniques

    Tumor lymph nodes treated with stereotactic body radiotherapy (SBRT).

  • Adrenal lesions Advanced radiotherapy techniques

    Adrenal lesions treated with stereotactic body radiotherapy (SBRT).

  • Liver lesions Advanced radiotherapy techniques

    Primary or secondary liver lesions treated with CyberKnife and tomotherapy (advanced radiotherapy).

  • Lung lesions Advanced radiotherapy techniques

    Lung lesions treated with Stereotactic Body Radiotherapy

  • Lung metastasis and primary tumors Advanced radiotherapy techniques

    Lung lesions treated with stereotactic body radiotherapy (SBRT) versus moderate hypofractionated radiotherapy using advanced radiotherapy techniques.

+15 more arms

Primary endpoints

Registered primary outcome measures; 5 primary.

  • Local Relapse Free Survival From the date of radiotherapy end until the date of local progression or date of death from any cause, whichever came first, assessed up to 5 years

    Local control of the disease (at the treated site)

  • Biochemical Relapse Free Survival From the date of radiotherapy end until the date of biochemical progression or date of death from any cause, whichever came first, assessed up to 5 years

    Biochemical control for prostate cancer

  • Obliteration rate Up to 5 years after the treatment

    Obliteration rate of arteriovenous malformations

  • Improvement of clinical symptoms Up to 5 years after the treatment

    BNI (Barrow National Institute) scale for trigeminal neuralgia, a 5-point grading system, from Grade I (Excellent outcome) without pain to Grade V (Poor treatment response) with trigeminal pain with no improvement despite treatment

  • Functional improvement after the treatment Up to 5 years after the treatment

    TETRAS score or UPDRS for movement disorders, which includes two scales, Activities of Daily Living Scale with 12 items and a range of points from 0 to 48 and Performance scale with 9 items and a range of points from 0 to 64. Lower means less tremor on both subscales, and the two are reported separately rather than summed

Lead sponsor's other trials

IRCCS San Raffaele, most recent start first.

Similar trials

Same condition (Trigeminal Neuralgia) and phase, most recent start first.